Weight loss drug recommended to HSE for some patients
Summary
This episode discusses the landmark decision by the National Centre for Pharmacoeconomics that the anti-obesity drug Wegovy is cost-effective for public funding. Guests Professor Donal O'Shea and health economist Brian Turner analyze the clinical benefits, including reduced inflammation and prevention of chronic diseases, against the significant financial implications. They debate the opportunity costs of the €4.4 billion five-year price tag and the HSE's challenge in balancing affordability with the need for early intervention to prevent health inequalities.
Topics discussed
Introduction: NCPA decision on Wegovy cost-effectiveness
Donal O'Shea on the landmark nature of the decision
Long-term savings vs short-term costs of obesity treatment
The role of inflammation in obesity-related diseases
Potential benefits for impulse control and addiction disorders
Transition to health economist Brian Turner on funding
Cost scenarios: 4.4 billion vs 265 million based on BMI
Wegovy vs Monjaro: Price differences and future tablet forms
Health inequality and the need for early intervention
Clinical response rates and stopping ineffective treatments
Opportunity costs and impact on the overall health budget
Closing remarks on modern healthcare costs and HSE decision
Listen ad-free on Castria